These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 30877602)

  • 1. Pharmacology of Nutraceuticals with Lipid Lowering Properties.
    Poli A; Visioli F
    High Blood Press Cardiovasc Prev; 2019 Apr; 26(2):113-118. PubMed ID: 30877602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper.
    Poli A; Barbagallo CM; Cicero AFG; Corsini A; Manzato E; Trimarco B; Bernini F; Visioli F; Bianchi A; Canzone G; Crescini C; de Kreutzenberg S; Ferrara N; Gambacciani M; Ghiselli A; Lubrano C; Marelli G; Marrocco W; Montemurro V; Parretti D; Pedretti R; Perticone F; Stella R; Marangoni F
    Pharmacol Res; 2018 Aug; 134():51-60. PubMed ID: 29859248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-lowering nutraceuticals update on scientific evidence.
    Derosa G; Colletti A; Maffioli P; D'Angelo A; Lupi A; Zito GB; Mureddu GF; Raddino R; Fedele F; Cicero AFG
    J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):845-859. PubMed ID: 32639326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nutraceuticals in lipid-lowering treatment: a narrative review on the role of chitosan.
    Patti AM; Katsiki N; Nikolic D; Al-Rasadi K; Rizzo M
    Angiology; 2015 May; 66(5):416-21. PubMed ID: 25037700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.
    ; ;
    Atherosclerosis; 2019 Nov; 290():140-205. PubMed ID: 31591002
    [No Abstract]   [Full Text] [Related]  

  • 6. A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence.
    Barrios V; Escobar C; Cicero AF; Burke D; Fasching P; Banach M; Bruckert E
    Atheroscler Suppl; 2017 Feb; 24():1-15. PubMed ID: 27998714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a new combination of nutraceuticals with Morus alba on lipid profile, insulin sensitivity and endotelial function in dyslipidemic subjects. A cross-over, randomized, double-blind trial.
    Trimarco V; Izzo R; Stabile E; Rozza F; Santoro M; Manzi MV; Serino F; Schiattarella GG; Esposito G; Trimarco B
    High Blood Press Cardiovasc Prev; 2015 Jun; 22(2):149-54. PubMed ID: 25870124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid.
    Mason RP; Libby P; Bhatt DL
    Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1135-1147. PubMed ID: 32212849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New trials in the scene of cardiovascular disease: innovation, controversy, and reassurance.
    Badimon L
    Cardiovasc Res; 2021 Mar; 117(4):e52-e54. PubMed ID: 33615348
    [No Abstract]   [Full Text] [Related]  

  • 10. News from ESC congress 2019: New ESC/EAS guidelines for dyslipidaemia management published.
    Stock J
    Atherosclerosis; 2019 Dec; 291():124-126. PubMed ID: 31668350
    [No Abstract]   [Full Text] [Related]  

  • 11. The effects of a nutraceutical combination on plasma lipids and glucose: A systematic review and meta-analysis of randomized controlled trials.
    Pirro M; Mannarino MR; Bianconi V; Simental-Mendía LE; Bagaglia F; Mannarino E; Sahebkar A
    Pharmacol Res; 2016 Aug; 110():76-88. PubMed ID: 27157250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Possible Role of Nutraceuticals in the Prevention of Cardiovascular Disease.
    Rivellese AA; Ciciola P; Costabile G; Vetrani C; Vitale M
    High Blood Press Cardiovasc Prev; 2019 Apr; 26(2):101-111. PubMed ID: 30811011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Management of Dyslipidaemia in Patients with Type 2 Diabetes Mellitus Receiving Lipid-Lowering Drugs: A Sub-Analysis of the CEPHEUS Findings.
    Shehab A; Al-Rasadi K; Arafah M; Al-Hinai AT; Al Mahmeed W; Bhagavathula AS; Al Tamimi O; Al Herz S; Al Anazi F; Al Nemer K; Metwally O; Alkhadra A; Fakhry M; Elghetany H; Medani AR; Yusufali AH; Al Jassim O; Al Hallaq O; Baslaib FOAS; Alawadhi M; Amin H; Al-Hashmi K; Oulhaj A
    Curr Vasc Pharmacol; 2018; 16(4):368-375. PubMed ID: 28677510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical controversies in lipid management.
    Tziomalos K
    Panminerva Med; 2015 Jun; 57(2):65-70. PubMed ID: 25669164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypolipidemic drugs in elderly subjects: Indications and limits.
    Gazzola K; Vigna GB
    Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1064-1070. PubMed ID: 27522161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dehydroepiandrosterone (DHEA) supplementation on the lipid profile: A systematic review and dose-response meta-analysis of randomized controlled trials.
    Qin Y; O Santos H; Khani V; Tan SC; Zhi Y
    Nutr Metab Cardiovasc Dis; 2020 Aug; 30(9):1465-1475. PubMed ID: 32675010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
    Cicero AFG; Fogacci F; Stoian AP; Vrablik M; Al Rasadi K; Banach M; Toth PP; Rizzo M
    Curr Atheroscler Rep; 2021 Aug; 23(10):57. PubMed ID: 34345932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-intensity lipid-lowering regimens in patients with stable coronary artery disease: the intriguing question of all-cause mortality.
    Danchin N; Simon T
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):328-330. PubMed ID: 31539045
    [No Abstract]   [Full Text] [Related]  

  • 19. Lipoprotein(a), the rediscovered risk factor, or how to get "back to the future".
    Sabouret P; Angoulvant D; Ray KK
    Arch Cardiovasc Dis; 2020 Mar; 113(3):147-151. PubMed ID: 32205042
    [No Abstract]   [Full Text] [Related]  

  • 20. Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets.
    Catapano AL
    Nat Rev Cardiol; 2018 Jan; 15(2):75-76. PubMed ID: 29336436
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.